nitrofural
Approved
Jul 1, 1945
Nitrofurazone is used to treat burns that have become infected. It is also used to treat skin infections due to skin grafts. It works by killing bacteria or preventing their growth. The exact mechanism of action is unknown. Nitrofurazone inhibits several bacterial enzymes, especially those involved in the aerobic and anaerobic degradation of glucose and pyruvate. The severe or irreversible adverse effects of Nitrofurazone, which give rise to further complications include Peripheral neuropathy, Thromboembolic disorder. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 8 marketing orgs
Earliest trial started Jul 1, 2020 (NCT04950647)
Timeline
1940s
- Jul 1, 1945
Earliest FDA Approval
- Oct 4, 1945
Shire — NDA Secondary Org
1970s
- Jun 5, 1975
Lannett Company, Inc. — Marketing Organization
- Oct 17, 1975
Shire — Marketing Organization
- Apr 26, 1978
Ambix — Marketing Organization
- Aug 15, 1978
Taro Pharmaceuticals — Marketing Organization
1980s
- May 11, 1981
Wendt — Marketing Organization
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Prodrug; its activated by the type I nitroreductase (NTR), who produces reactive species, leading to an increase in oxidative stress
Approval history
- approvedJul 1, 1945
Chemistry & pharmacology
SMILES
NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O- Mol. weight
- 198.1362 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaNitrofurazone ↗
- NCATSX8XI70B5Z6 ↗
- ChEMBLCHEMBL869 ↗
Also known as
- 5-nitro-2-furaldehyde semicarbazone
- 5-nitro-2-furaldehyde semicarbazone
- actin-n
- actin-n
- aldomycin
- babrocid
- furacilin
- furacilin
- furacilin
- furacilin
- furacin
- furacin
- furacin
- furacin
- furacine
- furacine
- furacine
- furacycline
- furaldon
- furaziline
- furazone
- furazone
- nifuzon
- nitrofural
- nitrofural
- nitrofural
- nitrofural
- nitrofural
- nitrofuraldehyde semicarbazone
- nitrofuran
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrofurazone
- nitrozone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04950647 | Phase 2 | Jul 1, 2020 | Peking University, Sichuan University |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ambix | For profit | MKTG | Apr 26, 1978 |
| Lannett Company, Inc. | For profit | MKTG | Jun 5, 1975 |
| Norwich Eaton Company | For profit | NDA | — |
| Perrigo | For profit | MKTG | — |
| Sherwood Medical | For profit | NDA2 | — |
| Shire | For profit | NDA2 | Oct 4, 1945 |
| Shire | For profit | MKTG | Oct 17, 1975 |
| Taro Pharmaceuticals | For profit | MKTG | Aug 15, 1978 |
| Wendt | For profit | MKTG | May 11, 1981 |